Immunic (IMUX) financial statements
Net income was -$97M.
Free cash flow was -$86M.
The diluted share count rose 4860% over the period (dilution).
Income statement
Fiscal years, from Immunic's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $30M | $39M | $10M | $23M | $39M | $61M | $71M | $83M | $80M | $82M |
| Selling, general and admin | $11M | $13M | $2M | $15M | $10M | $13M | $15M | $16M | $18M | $21M |
| Operating income | -$41M | -$53M | -$12M | -$37M | -$49M | -$92M | -$119M | -$99M | -$98M | -$103M |
| Pre-tax income | -$41M | -$52M | -$41M | — | — | — | — | — | — | — |
| Income tax | — | — | — | — | — | — | — | — | — | $0 |
| Net income | -$41M | -$52M | -$12M | -$35M | -$44M | -$93M | -$120M | -$94M | -$101M | -$97M |
| EPS (diluted) | -$13.10 | -$13.10 | -$136.30 | -$45.20 | -$28.10 | -$39.30 | -$37.80 | -$21.10 | -$1.00 | -$0.62 |
| Diluted shares | 3M | 4M | 0M | 1M | 2M | 2M | 3M | 4M | 100M | 156M |
Balance sheet
Fiscal years, from Immunic's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $60M | $57M | $13M | $29M | $127M | $87M | $107M | $47M | $36M | $15M |
| Total current assets | $61M | $58M | $13M | $32M | $134M | $105M | $126M | $53M | $39M | $23M |
| Property, plant and equipment | $3M | $2M | $40,000 | $80,000 | $203,000 | $152,000 | $294,000 | $466,000 | $545,000 | $608,000 |
| Goodwill | — | — | $0 | $33M | $33M | $33M | $0 | — | — | — |
| Total assets | $64M | $60M | $13M | $66M | $168M | $139M | $128M | $54M | $41M | $24M |
| Total current liabilities | $5M | $10M | $2M | $7M | $8M | $11M | $13M | $25M | $22M | $31M |
| Total liabilities | $6M | $74M | $2M | $8M | $9M | $12M | $14M | $25M | $22M | $31M |
| Shareholders' equity | $58M | -$13M | -$26M | $58M | $159M | $127M | $114M | $29M | $18M | -$7M |
| Net debt | -$60M | -$57M | -$13M | -$29M | -$127M | -$87M | -$107M | -$47M | -$36M | -$15M |
Cash flow
Fiscal years, from Immunic's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$36M | -$40M | -$10M | -$29M | -$46M | -$83M | -$65M | -$71M | -$85M | -$86M |
| Capital spending | $556,000 | $685,000 | $32,000 | $55,000 | $146,000 | $67,000 | $112,000 | $334,000 | $264,000 | $161,000 |
| Free cash flow | -$36M | -$41M | -$10M | -$29M | -$46M | -$83M | -$65M | -$71M | -$85M | -$86M |
| Stock-based compensation | $5M | $5M | $0 | $7M | $3M | $6M | $8M | $7M | $9M | $9M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for IMUX.
Open IMUX in InvestinglyQuestions
How much free cash flow does Immunic generate?
-$86M in fiscal 2025 (operating cash flow minus capital spending).
From Immunic's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.